# Dysregulated NFkB Pathway Signaling In Myeloproliferative Neoplasms

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2024 · $618,792

## Abstract

Project Summary/Abstract
Myeloproliferative neoplasms (MPNs) are chronic blood disorders that that can cause severe symptoms and
early death. New treatments have become available that help ameliorate symptoms, but they do not reliably slow
or halt disease progression. We seek to better understand what drives disease development and progression in
MPNs, so that we can develop better therapies for patients with these diseases.
Our preliminary data indicates that the NFkB pathway is abnormally activated in MPNs. We hypothesize that
NFkB pathway signaling contributes to the development of MPNs. Therefore, we have proposed a combination
of mouse and human studies to determine how NFkB contributes to MPN pathogenesis, and to evaluate whether
inhibition of NFkB pathway signaling may have potential therapeutic benefits for MPN patients.

## Key facts

- **NIH application ID:** 10802819
- **Project number:** 2R01HL134952-06A1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Stephen Oh
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $618,792
- **Award type:** 2
- **Project period:** 2017-12-11 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10802819

## Citation

> US National Institutes of Health, RePORTER application 10802819, Dysregulated NFkB Pathway Signaling In Myeloproliferative Neoplasms (2R01HL134952-06A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10802819. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*